<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21381" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Etanercept</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pan</surname>
            <given-names>Adrianne</given-names>
          </name>
          <aff>California Northstate University College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adrianne Pan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21381.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications. This activity describes the indications, action, and contraindications for etanercept as a valuable agent in managing these diseases and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management of patients with psoriasis, autoimmune arthritis, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of etanercept.</p></list-item><list-item><p>Describe the adverse effects of etanercept.</p></list-item><list-item><p>Review the appropriate monitoring and toxicity of etanercept.</p></list-item><list-item><p>Summarize some interprofessional team strategies for improving care coordination and communication to advance etanercept and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21381&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21381">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21381.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Etanercept is a biologic TNF inhibitor commonly used to&#x000a0;control ankylosing spondylitis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. Etanercept is a&#x000a0;soluble receptor that binds both TNF-alpha and TNF-beta to inhibit the inflammatory response in joints and skin that is characteristic of these autoimmune disorders.&#x000a0;The drug can be&#x000a0;used as a monotherapy or taken with other immunosuppressants, such as methotrexate.<xref ref-type="bibr" rid="article-21381.r1">[1]</xref></p>
        <p>Clinicians can use etanercept for both approved and off-label indications.<xref ref-type="bibr" rid="article-21381.r2">[2]</xref><xref ref-type="bibr" rid="article-21381.r3">[3]</xref><xref ref-type="bibr" rid="article-21381.r4">[4]</xref><xref ref-type="bibr" rid="article-21381.r5">[5]</xref></p>
        <p>
<bold>FDA Approved Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ankylosing spondylitis</p>
          </list-item>
          <list-item>
            <p>Juvenile idiopathic arthritis (2 years or older)</p>
          </list-item>
          <list-item>
            <p>Plaque psoriasis (4 years or older)</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
        </list>
        <p>
<bold>Off-label Uses (not FDA approved)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute graft-versus-host disease (combined with methylprednisolone)</p>
          </list-item>
          <list-item>
            <p>Behcet disease</p>
          </list-item>
          <list-item>
            <p>Hidradenitis suppurativa&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Kawasaki disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pemphigus vulgaris&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pustular psoriasis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pyoderma gangrenosum&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Scleroderma/systemic sclerosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Still disease&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21381.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Etanercept is a biologic tumor necrosis factor (TNF) inhibitor; the drug acts as a soluble TNF receptor and binds TNF-alpha and TNF-beta.<xref ref-type="bibr" rid="article-21381.r6">[6]</xref> TNF is a cytokine that can bind to TNF receptor 1 (TNFR1) or TNF receptor 2 (TNFR2) and is involved in inflammation and the immune response.<xref ref-type="bibr" rid="article-21381.r7">[7]</xref>&#x000a0;TNF binds to TNFR1 or TNFR2, activating important inflammatory pathways, such as NFkB and MAPK. The structure of etanercept consists of two p75 TNF receptors fused to the Fc portion of human IgG.<xref ref-type="bibr" rid="article-21381.r6">[6]</xref> Etanercept works by blocking the effects of TNF-alpha, a pro-inflammatory cytokine that becomes elevated in psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis.</p>
      </sec>
      <sec id="article-21381.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Etanercept administration is via subcutaneous injection, usually on the thigh, lower abdomen, or upper arm. If given on the abdomen, the injection should not be within the 2-inch area around the navel. Injections should be administered at least 1 inch away from previous injection sites. The medication comes in a pre-filled syringe, automatic injection device, or multiple-dose vial. After the initial injection of etanercept at the clinician&#x02019;s office, the patient can self-inject at home with appropriate training.<xref ref-type="bibr" rid="article-21381.r8">[8]</xref></p>
        <p>To treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, 50 mg of etanercept is injected once a week. An alternative dosing regimen is 25 mg subcutaneously twice weekly, with at least 72 to 96 hours between injections. For psoriasis, the dosage is 50 mg twice weekly for three months, followed by 50 mg once weekly. Children with juvenile idiopathic arthritis are administered 0.8 mg/kg once a week, up to 50 mg.</p>
      </sec>
      <sec id="article-21381.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Infection (viral, bacterial, and fungal &#x02013; mostly upper respiratory tract infections)</p>
          </list-item>
          <list-item>
            <p>Injection site reaction (erythema, itching, pain, swelling, bleeding, bruising)<xref ref-type="bibr" rid="article-21381.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Rare Adverse Effects (in alphabetical order):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Blood and lymph disorders: aplastic anemia, leukopenia, myelodysplastic syndrome, neutropenia,&#x000a0;pancytopenia, thrombocytopenia<xref ref-type="bibr" rid="article-21381.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Cancers: lymphoma, skin cancers<xref ref-type="bibr" rid="article-21381.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Cardiopulmonary problems: congestive heart failure, interstitial lung disease<xref ref-type="bibr" rid="article-21381.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Gastrointestinal and liver problems: autoimmune hepatitis,<xref ref-type="bibr" rid="article-21381.r12">[12]</xref> diarrhea,<xref ref-type="bibr" rid="article-21381.r13">[13]</xref> elevated transaminases,<xref ref-type="bibr" rid="article-21381.r14">[14]</xref> inflammatory bowel disease,<xref ref-type="bibr" rid="article-21381.r15">[15]</xref> nausea<xref ref-type="bibr" rid="article-21381.r16">[16]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Immune and inflammatory conditions: &#x000a0;angioedema,<xref ref-type="bibr" rid="article-21381.r17">[17]</xref> hypersensitivity reaction,<xref ref-type="bibr" rid="article-21381.r18">[18]</xref> lupus-like syndrome,<xref ref-type="bibr" rid="article-21381.r11">[11]</xref> non-neutralizing anti-Etanercept antibodies,<xref ref-type="bibr" rid="article-21381.r1">[1]</xref> pyrexia,<xref ref-type="bibr" rid="article-21381.r16">[16]</xref> sarcoidosis, uveitis, vasculitis</p>
          </list-item>
          <list-item>
            <p>Infections: aspergillosis,<xref ref-type="bibr" rid="article-21381.r19">[19]</xref> candidiasis,<xref ref-type="bibr" rid="article-21381.r19">[19]</xref> coccidioidomycosis, cryptococcus,<xref ref-type="bibr" rid="article-21381.r19">[19]</xref> herpes zoster, histoplasmosis,<xref ref-type="bibr" rid="article-21381.r19">[19]</xref> legionella pneumonia,<xref ref-type="bibr" rid="article-21381.r20">[20]</xref> listeriosis,<xref ref-type="bibr" rid="article-21381.r19">[19]</xref> nocardiosis,<xref ref-type="bibr" rid="article-21381.r19">[19]</xref> pneumocystis pneumonia, reactivation of Hepatitis B or&#x000a0;TB,<xref ref-type="bibr" rid="article-21381.r21">[21]</xref> salmonella infection,<xref ref-type="bibr" rid="article-21381.r19">[19]</xref> septic arthritis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nervous system disorders: headache,<xref ref-type="bibr" rid="article-21381.r5">[5]</xref> multiple sclerosis, optic neuritis, paresthesias, seizures, transverse myelitis</p>
          </list-item>
          <list-item>
            <p>Skin disorders: cutaneous lupus erythematosus,<xref ref-type="bibr" rid="article-21381.r22">[22]</xref> erythema multiforme,<xref ref-type="bibr" rid="article-21381.r22">[22]</xref> new or worsening psoriasis, rash, Stevens-Johnson syndrome,<xref ref-type="bibr" rid="article-21381.r22">[22]</xref> toxic epidermal necrolysis,<xref ref-type="bibr" rid="article-21381.r22">[22]</xref> urticaria</p>
          </list-item>
        </list>
        <p>
<bold>US Boxed warnings</bold>
</p>
        <p>
<bold>Infections, Including Tuberculosis</bold>
</p>
        <p>Patients using etanercept have an increased risk of acquiring serious and/or fatal infections, including the development of active tuberculosis or reactivation of latent tuberculosis. There are reports of various bacterial, viral, and fungal infections, including invasive fungal (aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and opportunistic infections (legionellosis, listeriosis).&#x000a0;</p>
        <p>Infections were more common in patients that received adjunct immunosuppressive medications, such as methotrexate or corticosteroids. Medical providers should exercise caution when prescribing etanercept to patients at higher risk for infections, including elderly patients, immunocompromised patients, patients with a history of recurrent/chronic/opportunistic infections, and patients exposed to tuberculosis or endemic mycoses. Physicians should consider empiric antifungal therapy for patients living in or traveling to endemic areas with an increased risk of invasive fungal infections.</p>
        <p>
<bold>Malignancies</bold>
</p>
        <p>Reports exist of malignancies in patients receiving etanercept, especially in children and adolescents. Lymphomas were most commonly reported, followed by melanoma and other skin cancers. Though the connection between etanercept and malignancies is not fully understood, clinical trials and case reports showed an increased rate of lymphoma and other malignancies in patients on etanercept compared to the general population. However, it is worth noting that rheumatoid arthritis alone has associations with increased rates of lymphoma and leukemia.<xref ref-type="bibr" rid="article-21381.r23">[23]</xref></p>
      </sec>
      <sec id="article-21381.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Etanercept contraindications include patients with sepsis. Patients should not start etanercept during active bacterial infections, including tuberculosis (active or latent), active herpes zoster infection, active or chronic untreated Hepatitis B or C infection, or active invasive fungal infections.<xref ref-type="bibr" rid="article-21381.r24">[24]</xref> Patients should not use etanercept if they have a hypersensitivity reaction to the medication ingredients.</p>
      </sec>
      <sec id="article-21381.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before starting etanercept, patients should receive screening for any infections, including latent tuberculosis or hepatitis B. Patients on etanercept require monitoring for signs of infection and reactivation or development of tuberculosis and hepatitis B.<xref ref-type="bibr" rid="article-21381.r25">[25]</xref> If a severe infection or sepsis develops during etanercept treatment, discontinue treatment. Also, patients should be monitored for signs or symptoms of hypersensitivity reactions, malignancy, or lupus-like syndrome. Patients with a history of heart failure also require monitoring during etanercept treatment.<xref ref-type="bibr" rid="article-21381.r26">[26]</xref></p>
      </sec>
      <sec id="article-21381.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There have not been any dose-limiting toxicities observed during clinical trials, in vivo, and in vitro studies. However, the long-term toxicity of etanercept treatment is unknown.<xref ref-type="bibr" rid="article-21381.r27">[27]</xref></p>
      </sec>
      <sec id="article-21381.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Etanercept is one of several different options for treating plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. The medical providers should weigh the risks and benefits of selecting etanercept as a treatment, such as drug cost, effectiveness, method of administration, and adverse effects. Because it is a biologic, etanercept usage comes with serious side effects such as infections, malignancies, and autoimmune conditions.</p>
        <p>An interprofessional team of clinicians, specialists, nurses, and pharmacists must work together to ensure the safety and wellbeing of the patient. When&#x000a0;deciding to treat with etanercept, clinicians should know the treatment guidelines, including monitoring the patient for signs of heart failure, tuberculosis, hepatitis B, and other infections before and during treatment. Clinicians and nurses will instruct the patient or the patient&#x02019;s relative on properly administering&#x000a0;etanercept injections at home. Clinicians and pharmacists must ensure that the patient receives the proper medication and dosage and that the patient receives on drug interactions and adverse effects. Nursing can participate in injection administration training and education and should keep the team informed regarding the appearance of&#x000a0;any adverse reactions, as well as monitoring the success/failure of therapy. Also, biosimilars of etanercept have been emerging on the market, so healthcare providers need to be kept abreast regarding the different options that they have for treatment.<xref ref-type="bibr" rid="article-21381.r28">[28]</xref><xref ref-type="bibr" rid="article-21381.r29">[29]</xref> Without proper management, the quality of life in patients with these diseases is low. An interprofessional healthcare team can help achieve the best possible outcomes with minimal adverse events. [Level 5]</p>
      </sec>
      <sec id="article-21381.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21381&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21381">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21381/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21381">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21381.s11">
        <title>References</title>
        <ref id="article-21381.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Van Der Heijde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cush</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clegg</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Kivitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fleischmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>W</given-names>
              </name>
              <collab>Enbrel Ankylosing Spondylitis Study Group</collab>
            </person-group>
            <article-title>Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>3230</fpage>
            <page-range>3230-6</page-range>
            <pub-id pub-id-type="pmid">14613288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lovell</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Reiff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cawkwell</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Nocton</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Gedalia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ilowite</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Whitmore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Finck</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Mar</month>
            <day>16</day>
            <volume>342</volume>
            <issue>11</issue>
            <fpage>763</fpage>
            <page-range>763-9</page-range>
            <pub-id pub-id-type="pmid">10717011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papp</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lahfa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prinz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Zitnik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van de Kerkhof</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Melvin</surname>
                <given-names>L</given-names>
              </name>
              <collab>Etanercept Psoriasis Study Group</collab>
            </person-group>
            <article-title>A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.</article-title>
            <source>Br J Dermatol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>152</volume>
            <issue>6</issue>
            <fpage>1304</fpage>
            <page-range>1304-12</page-range>
            <pub-id pub-id-type="pmid">15948997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mease</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kivitz</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Ory</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salonen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.</article-title>
            <source>Arthritis Rheum</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>2264</fpage>
            <page-range>2264-72</page-range>
            <pub-id pub-id-type="pmid">15248226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreland</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tindall</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Fleischmann</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bulpitt</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Keystone</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Mease</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ruderman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Arkfeld</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Garrison</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burge</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Blosch</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>McDonnell</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Weinblatt</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.</article-title>
            <source>Ann Intern Med</source>
            <year>1999</year>
            <month>Mar</month>
            <day>16</day>
            <volume>130</volume>
            <issue>6</issue>
            <fpage>478</fpage>
            <page-range>478-86</page-range>
            <pub-id pub-id-type="pmid">10075615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tracey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sasso</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Salfeld</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Tak</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.</article-title>
            <source>Pharmacol Ther</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>117</volume>
            <issue>2</issue>
            <fpage>244</fpage>
            <page-range>244-79</page-range>
            <pub-id pub-id-type="pmid">18155297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mocci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Armuzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guidi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.</article-title>
            <source>J Crohns Colitis</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>769</fpage>
            <page-range>769-79</page-range>
            <pub-id pub-id-type="pmid">23453887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van den Bemt</surname>
                <given-names>BJF</given-names>
              </name>
              <name>
                <surname>Gettings</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Doma&#x00144;ska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bruggraber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mountian</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience.</article-title>
            <source>Drug Deliv</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>384</fpage>
            <page-range>384-392</page-range>
            <pub-id pub-id-type="pmid">30905213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feltelius</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fored</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Blomqvist</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bertilsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Geborek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jacobsson</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Lindblad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lysholm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rantap&#x000e4;&#x000e4;-Dahlqvist</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saxne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <collab>ARTIS Group</collab>
            </person-group>
            <article-title>Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-52</page-range>
            <pub-id pub-id-type="pmid">15208177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Gershon</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.</article-title>
            <source>Arthritis Rheum</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>3151</fpage>
            <page-range>3151-8</page-range>
            <pub-id pub-id-type="pmid">12483718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brito-Zer&#x000f3;n</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soria</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Galiana</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bertolaccini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cuadrado</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Khamashta</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>86</volume>
            <issue>4</issue>
            <fpage>242</fpage>
            <page-range>242-251</page-range>
            <pub-id pub-id-type="pmid">17632266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>French</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bonacini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghabril</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Foureau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity Associated with the Use of Anti-TNF-&#x003b1; Agents.</article-title>
            <source>Drug Saf</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-208</page-range>
            <pub-id pub-id-type="pmid">26692395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Da Silva</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Horst-Bruinsma</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Juanola</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Raeman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Settas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szechinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boussuge</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Wajdula</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Paolozzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fatenejad</surname>
                <given-names>S</given-names>
              </name>
              <collab>Etanercept Study 314 Investigators</collab>
            </person-group>
            <article-title>Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>12</issue>
            <fpage>1572</fpage>
            <page-range>1572-7</page-range>
            <pub-id pub-id-type="pmid">16968715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akhlaghi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahebari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahmoodi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yaseri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mansournia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rafatpanah</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zeraati</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>1943</fpage>
            <page-range>1943-1950</page-range>
            <pub-id pub-id-type="pmid">30349273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Toole</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Korzenik</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA.</article-title>
            <source>Dig Dis Sci</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>1772</fpage>
            <page-range>1772-4</page-range>
            <pub-id pub-id-type="pmid">26728477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lovell</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Reiff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>OY</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Gedalia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ilowite</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Finck</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Burge</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>Pediatric Rheumatology Collaborative Study Group</collab>
            </person-group>
            <article-title>Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>218</fpage>
            <page-range>218-26</page-range>
            <pub-id pub-id-type="pmid">12528122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sendur</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Berkit</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Tastaban</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Angio-oedema in a patient treated with etanercept for rheumatoid arthritis.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>104</volume>
            <issue>6</issue>
            <fpage>488</fpage>
            <page-range>488-90</page-range>
            <pub-id pub-id-type="pmid">19371261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puxeddu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Caltran</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rocchi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Del Corso</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tavoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Migliorini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity reactions during treatment with biological agents.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-32</page-range>
            <pub-id pub-id-type="pmid">26751942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallis</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Broder</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Beenhouwer</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Granulomatous infectious diseases associated with tumor necrosis factor antagonists.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>May</month>
            <day>01</day>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>1261</fpage>
            <page-range>1261-5</page-range>
            <pub-id pub-id-type="pmid">15127338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanternier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tubach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ravaud</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salmon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dellamonica</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bretagne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Couret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bouvard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Debandt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gueit</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gendre</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nicolas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Che</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mariette</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
              <collab>Research Axed on Tolerance of Biotherapies Group</collab>
            </person-group>
            <article-title>Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.</article-title>
            <source>Chest</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>144</volume>
            <issue>3</issue>
            <fpage>990</fpage>
            <page-range>990-998</page-range>
            <pub-id pub-id-type="pmid">23744173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cantini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Niccoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goletti</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance.</article-title>
            <source>J Rheumatol Suppl</source>
            <year>2014</year>
            <month>May</month>
            <volume>91</volume>
            <fpage>47</fpage>
            <page-range>47-55</page-range>
            <pub-id pub-id-type="pmid">24789000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerbleski</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Dermatological complications and safety of anti-TNF treatments.</article-title>
            <source>Gut</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>1033</fpage>
            <page-range>1033-9</page-range>
            <pub-id pub-id-type="pmid">19592682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2020</year>
            <month>Jul</month>
            <day>01</day>
            <volume>156</volume>
            <issue>7</issue>
            <fpage>787</fpage>
            <page-range>787-794</page-range>
            <pub-id pub-id-type="pmid">32432649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Bridges</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vaysbrot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McNaughton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Osani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shmerling</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Dell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Schousboe</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Drevlow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grober</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Tindall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>T</given-names>
              </name>
              <collab>American College of Rheumatology</collab>
            </person-group>
            <article-title>2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-25</page-range>
            <pub-id pub-id-type="pmid">26545825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thalayasingam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Anti-TNF therapy.</article-title>
            <source>Best Pract Res Clin Rheumatol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>549</fpage>
            <page-range>549-67</page-range>
            <pub-id pub-id-type="pmid">22137924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenblum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amital</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Anti-TNF therapy: safety aspects of taking the risk.</article-title>
            <source>Autoimmun Rev</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>563</fpage>
            <page-range>563-8</page-range>
            <pub-id pub-id-type="pmid">21570495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>HZ</given-names>
              </name>
            </person-group>
            <article-title>Biologics in the treatment of pustular psoriasis.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>969</fpage>
            <page-range>969-980</page-range>
            <pub-id pub-id-type="pmid">32615817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bae</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Shim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>Y</given-names>
              </name>
              <collab>HERA Study Investigators</collab>
            </person-group>
            <article-title>A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-71</page-range>
            <pub-id pub-id-type="pmid">26905864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21381.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tomomitsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hagino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YW</given-names>
              </name>
            </person-group>
            <article-title>Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>488</fpage>
            <page-range>488-494</page-range>
            <pub-id pub-id-type="pmid">29259050</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
